Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVDL
CUSIPN/A
Phone636-449-1830
Debt
Debt-to-Equity Ratio1.44
Current Ratio3.39
Quick Ratio3.28
Price-To-Earnings
Trailing P/E Ratio14.39
Forward P/E Ratio-2.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$172.74 million
Price / Sales0.95
Cash Flow$0.4252 per share
Price / Cash10.49
Book Value$2.18 per share
Price / Book2.05
Profitability
EPS (Most Recent Fiscal Year)$0.31
Net Income$68.27 million
Net Margins-2.39%
Return on Equity-46.58%
Return on Assets-13.75%
Miscellaneous
Employees180
Outstanding Shares36,740,000
Market Cap$172.70 million
Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions
What is Avadel Pharmaceuticals' stock symbol?
Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
How will Avadel Pharmaceuticals' stock buyback program work?
Avadel Pharmaceuticals declared that its board has approved a share buyback plan on Wednesday, March 28th 2018, which authorizes the company to buyback $7,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.7% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.
How were Avadel Pharmaceuticals' earnings last quarter?
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) released its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.09) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.28. The company had revenue of $29.23 million for the quarter, compared to the consensus estimate of $25.02 million. Avadel Pharmaceuticals had a negative net margin of 2.39% and a negative return on equity of 46.58%. View Avadel Pharmaceuticals' Earnings History.
When is Avadel Pharmaceuticals' next earnings date?
What price target have analysts set for AVDL?
5 brokers have issued 1-year target prices for Avadel Pharmaceuticals' shares. Their predictions range from $14.00 to $30.00. On average, they expect Avadel Pharmaceuticals' share price to reach $22.6667 in the next twelve months. This suggests a possible upside of 408.2% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.
What is the consensus analysts' recommendation for Avadel Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.
Who are some of Avadel Pharmaceuticals' key competitors?
Some companies that are related to Avadel Pharmaceuticals include ArQule (ARQL), Vectura Group (VEGPF), ANI Pharmaceuticals Inc Common Stock (ANIP), Eidos Therapeutics (EIDX), Dova Pharmaceuticals (DOVA), Abeona Therapeutics (ABEO), Viking Therapeutics (VKTX), CannTrust (CNTTF), GlycoMimetics (GLYC), Adamas Pharmaceuticals (ADMS), Verastem (VSTM), Homology Medicines (FIXX), Urogen Pharma (URGN), Arcus Biosciences (RCUS) and Progenics Pharmaceuticals (PGNX).
Who are Avadel Pharmaceuticals' key executives?
Avadel Pharmaceuticals' management team includes the folowing people:
- Mr. Michael S. Anderson, CEO & Director (Age 69)
- Mr. Michael F. Kanan, Sr. VP & CFO (Age 55)
- Mr. Gregory J. Divis, Exec. VP & COO (Age 53)
- Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
- Dr. David Monteith, VP of R&D (Age 54)
Has Avadel Pharmaceuticals been receiving favorable news coverage?
News coverage about AVDL stock has been trending somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a media and rumor sentiment score of 0.13 on Accern's scale. They also gave news coverage about the company an impact score of 46.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Avadel Pharmaceuticals.
Who are Avadel Pharmaceuticals' major shareholders?
Avadel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (13.53%), Acadian Asset Management LLC (3.62%), Renaissance Technologies LLC (2.86%), BlackRock Inc. (1.33%), Millennium Management LLC (0.90%) and GSA Capital Partners LLP (0.64%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Francis Fildes, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, James E Flynn, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.
Which institutional investors are selling Avadel Pharmaceuticals stock?
AVDL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, GSA Capital Partners LLP, Portolan Capital Management LLC, BlackRock Inc., Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include Craig R Stapleton, James E Flynn, Michael S Anderson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.
Which institutional investors are buying Avadel Pharmaceuticals stock?
AVDL stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Brandes Investment Partners LP, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Investors Asset Management of Georgia Inc. GA ADV and Quantitative Systematic Strategies LLC. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.
How do I buy shares of Avadel Pharmaceuticals?
Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avadel Pharmaceuticals' stock price today?
One share of AVDL stock can currently be purchased for approximately $4.46.
How big of a company is Avadel Pharmaceuticals?
Avadel Pharmaceuticals has a market capitalization of $172.70 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.
How can I contact Avadel Pharmaceuticals?
Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]
MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
